FHTX — Foghorn Therapeutics. Cashflow Statement
0.000.00%
Last trade - 00:00
- $254.97m
- $20.91m
- $34.16m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -51.1 | -68.8 | -101 | -109 | -98.4 |
Depreciation | |||||
Non-Cash Items | 2.9 | 7.48 | 14.4 | 17.6 | 18.7 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.2 | 28.7 | 33.4 | 282 | -41.9 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -46.3 | -31.3 | -50.3 | 194 | -118 |
Capital Expenditures | -0.968 | -16.2 | -3.31 | -1.21 | -1.22 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 0.004 | -92.7 | 39.5 | -243 | 146 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.964 | -109 | 36.2 | -244 | 144 |
Financing Cash Flow Items | — | — | 42.2 | 0 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 24 | 217 | 22.4 | 1.76 | 1.78 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -23.3 | 77.3 | 8.34 | -48.9 | 28.1 |